Drugs / AUR-201
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06225336 | Nov 2022 → Sep 2025 | microtia | Auregen Biotherapeutics, SA | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06072040 | Jan 2024 → Nov 2025 | microtia | Auregen Biotherapeutics, SA | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT06078566 | Jan 2024 → Nov 2025 | microtia | Auregen Biotherapeutics, SA | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AUR-201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06072040 ↗ |
| Modality | Cell therapy | “3-D printed autologous auricular sourced chondrocytes” NCT06072040 ↗ |
| Route | Subcutaneous | “subcutaneous implant” NCT06072040 ↗ |